

Cincinnati Children's Innovation Ventures (CCIV) / Inventor Service Level Expectations (SLE)

Outline of this Document

- [Why work with CCIV](#)
- [What is CCIV](#)
- [How to work with CCIV](#)
 - [Research Tools](#)
 - [Commercialization](#)
 - [Sponsored Research](#)

Why Work with CCIV

Why Work with CCIV

- [Innovate Together with Cincinnati Children's Innovation Ventures](#)
- Research or institutional experiences often lead to new ideas or discoveries that can benefit the public
- Typically, publication alone is not enough to ensure that the market will adopt an innovation
- We partner with companies or organizations that can make new products available to the market.
- Ensure we have the rights to transfer research materials
- Protect your interests when sending research materials or receiving funding (e.g., acknowledgement, publication, appropriate use, maintaining control of important background intellectual property)

Why Work with CCIV

- Bringing a product to market likely requires further research or clinical trials and is **expensive**
- Industry generally prefers to invest in a technology that has intellectual property protection – exclusivity creates the **incentive to invest** in the process when the relative cost of copying the product is low
- If you want to share in any **future revenue** generated from licensing your innovation

What is CCIV

Functional Groups

Portfolio Management

- Initial Review of all new technologies
- Responsible for managing the bulk of the portfolio
- Maintains primary Inventor(s) relationship
- Negotiates and Executes agreements related to portfolio technologies
- Submits technologies for Acceleration

Acceleration Management

- Each Manager is responsible for 1-5 projects, each encompassing 1 or more technologies.
- Provides in depth strategy for technology development
- Works closely with Inventor(s) to decide on strategy and collaborate on the needs for the technology
- Negotiates and Executes agreements related to Acceleration technologies

Patent Management

- Requests input from Innovation Ventures colleagues and Inventors to consider patent strategy
- Provides input to Innovation Ventures and Inventors around patent strategy
- Manages relationships with outside patent counsel

Program Management

- Develops ongoing relationships with long-term partners that fund development of CCHMC technologies
- Manages internal and external funding programs to help develop CCHMC technologies

Marketing

- Assists with market and competitive research
- Identifies marketing leads at companies we do not have existing relationships with
- Standardizes external and internal communications from Innovation Ventures
- Designs educational opportunities related to innovation within CCHMC

Finance & Data Management

- Receives and distributes revenue received by our licensees
- Manages payment to patent counsel and other vendors
- Manages our internal database
- Reports inventions to government funders

CCIV Programs and Development Opportunities

Innovation Fund

An internal development fund with RFPs 2x/year

BridgeBio Research Alliance

Multi-year collaboration to advance transformational therapies

BioMarin Open Innovation Program

Focused on genetic-based diseases of at least 1:50,000

Pfizer Centers for Therapeutic Innovation (CTI)

Novel Targets in Inflammation & Immunology, Internal Medicine, Oncology, and Rare Diseases

Sanofi Innovation Awards (iAwards)

Therapeutics in immune-oncology, molecular oncology, immunology & inflammation, rare diseases, diabetes, and cardiovascular diseases

Takeda Research Collaboration

Multi-year collaboration to advance early-stage CNS, oncology, GI, and rare disease therapeutics

CCHMC Translational Core Labs

Vector design and manufacturing resources

Venture Partnerships

CincyTech, Orange Grove Bio, Fortress, Roivant, 5AM, and others

Ohio Third Frontier Technology Validation Start-up Fund (TVSF)

Ben-Gurion Cincinnati Children's Collaborative (KidStart in Israel)

Medical device and digital health co-innovation



Our Portfolio Asset Classes



**Small Molecule
Therapies**



**Biologic, Cell &
Gene Therapies**




**Diagnostics &
Medical Devices**



**Digital Health &
Care Delivery**

[Find CCIV](#) on: CenterLink's Research tab (or keyword search "ventures")

Our Org Chart



How to Work with CCIV

When to disclose?

- Publication or presentation before a patent filing usually results in the **inability** to ultimately get a patent
- So, **disclose to Innovation Ventures at least 30 days *before* you publish or present** so we can discuss if IP makes sense in your case

Where to start?

AT LEAST 30 DAYS BEFORE submitting a manuscript or speaking at a conference, be sure to contact us

- Submit a disclosure via the [Inventor Portal](#)
 - See [Types of Disclosures](#)
- Contact information can be found on our [Centerlink Page](#)

Key information includes:

- The names of the Inventor(s), their respective institution, and their contributions
- Any funding received to support the invention and associated grant numbers
- A detailed description of the invention, along with a brief statement indicating what the invention is and what it can be used for
- A copy of any anticipated dissertation, poster, presentation, manuscript, etc, if available, and the date of planned publication or presentation
- Any 3rd party materials used in creating/developing the invention

Types of Disclosures

Invention Disclosures – ideas with some proof of concept

- Therapeutic & Diagnostic Asset Classes: may include in vitro or in vivo data justifying a novel target, validation of a novel target, pharmacologic evidence that modulating a novel target may treat an indication, a novel and proprietary therapeutic approach, or validated markers with AUC better than current standard of care
- Medical Device, Digital Health and Care Delivery Asset Classes: may include a potential designs or solutions that are devices, software or informational; a 3D printed model; a software wireframe; or a working device or software prototype

Research & Development Disclosures (RDs) – early-stage concepts

- Therapeutic & Diagnostic Asset Classes: early-stage data supporting a novel mechanism or marker that could lead to improvement of clinical care
- Medical Device, Digital Health and Care Delivery Asset Classes: identification of a patient need or clinical need at the concept stage or earlier

Research Tool Disclosures (RTs) – items for use by other researchers

- Biologic Research Tools: include proteins, cell lines, and animal models
- Copyright Research Tools: include research software, questionnaires, surveys, and manuals

How to Work with CCIV

Process & Expectations

CCIV Processes

1. [Commercialization Process of Invention Disclosures and R&D Disclosures](#)
2. [Sending and Receipt of Biologic and Copyright Research Tools](#)
3. [Sponsored Research](#)

1. Commercialization Process of Invention Disclosures (with proof of concept) and R&D Disclosures (without proof of concept)

CCIV Commercialization Process Overview

EVALUATION


Disclosure Submission & Acknowledgement

- Acknowledgement \leq 3 business days of disclosure submission; Urgent patent filing decision within \leq 14 days



Disclosure Reporting & Assessment

- \leq 30 days of disclosure submission



Review Process & Disposition

- \leq 120 days of meeting with Inventor(s)



MANAGEMENT

Initial Commercial Strategy

- \leq 30 days of Review Process & Disposition



Intellectual Property Management

- Timelines determined by patent offices



Marketing

- Ongoing once technology reaches "Marketing" status



Agreement Due Diligence, Negotiation, & Execution

- Timeline determined by partner
- Innovation Ventures to follow up every 2 weeks



CCIV Commercialization Process Overview

EVALUATION

Disclosure Submission & Acknowledgement

- Acknowledgement \leq 3 business days of disclosure submission; Urgent patent filing decision within \leq 14 days

Disclosure Reporting & Assessment

- \leq 30 days of disclosure submission

Review Process & Disposition

- \leq 120 days of meeting with Inventor(s)

MANAGEMENT

Initial Commercial Strategy

- \leq 30 days of Review Process & Disposition

Intellectual Property Management

- Timelines determined by patent offices

Marketing

- Ongoing once technology reaches "Marketing" status

Agreement Due Diligence, Negotiation, & Execution

- Timeline determined by partner
- Innovation Ventures to follow up every 2 weeks

Disclosure Submission and Acknowledgment



Disclosure Reporting and Assessment



Review Process and Disposition

Inventor(s)**≥ 30 days prior to a public release**

- Submit a disclosure 30 days prior to a dissertation, publication, poster, abstract, public presentation, discussions outside of immediate collaborators, or other public release
- Fill out a complete disclosure, and respond to any requested missing information
- For federal reporting requirements, this, at a minimum, includes:
 - The names of the Inventor(s)s, their respective institution, and their contributions
 - Any funding received to support the invention and associated grant numbers
 - A detailed description of the invention, along with a brief statement indicating what the invention is and what it can be used for
 - A copy of any anticipated dissertation, poster, presentation, manuscript, etc, if available, and the date of planned publication or presentation
 - Any 3rd party materials used in creating/developing the invention

Innovation Ventures**≤ 3 business days of Disclosure Submission**


- Assigned to a portfolio manager
- Deliverables:
 - Automated email from CCIV software acknowledging receipt

≤ 14 days of Disclosure Submission


- Confirm all necessary information is included in the disclosure
- Will review Inventors' publication timeline to understand if any urgent decisions need to be made
- Deliverables:
 - Email from portfolio manager to Inventor(s) acknowledging receipt
 - Communication if a patent will be filed prior to any imminent public disclosure

CCIV Commercialization Process Overview

EVALUATION



MANAGEMENT



EVALUATION

Disclosure Submission
and Acknowledgment



Disclosure Reporting & Assessment



Review Process
and Disposition

Inventor(s)

≤ 60 days of completed disclosure

- Iterative meetings to provide Innovation Ventures with sufficient understanding of the invention
- To the extent known, provide Innovation Ventures with relevant background publications, unpublished data related to the invention, grant submissions, details related to the potential customer or patient, and academic colleagues and/or industry working in the space
- Report inventions on grant close-out forms, as needed


Innovation Ventures

≤ 30 days of completed disclosure


- Report to sponsor, if any. Should match inventions on grant close-out forms completed by Inventor(s)
- Review and log any 3rd party obligations (e.g., funding agreements, material transfer agreements)
- Reach out to any institution that is a co-owner to the invention
- Deliverable:
 - Meeting with Inventor(s) to be scheduled

CCIV Commercialization Process Overview

EVALUATION



MANAGEMENT



EVALUATION

Disclosure Submission
and Acknowledgment



Disclosure Reporting
and Assessment



Review Process and Disposition

Inventor(s)

≤ 90 days of completed disclosure

- Allow Innovation Ventures to confidentially share invention information with internal and external reviewers
- Availability to answer questions from Innovation Ventures or reviewers
- Availability to discuss strategy of commercialization with Innovation Ventures

Innovation Ventures

≤ 120 days of meeting with Inventor(s)

- If a patent was filed, there may be further search of patent/publication literature
- Deliverables:
 - Determination by Innovation Ventures whether institution will pursue commercialization, or if [Inventor\(s\) Driven or Shared Responsibility](#)

Disposition Options

Brief Description

Inventor(s) Driven Experimentation based on CCIV Feedback - ~ 40 projects per Portfolio Manager

- Technology enters Innovation Ventures portfolio, but requires additional development by Inventor(s)
- Intellectual property determined by Innovation Ventures in conjunction with Inventor(s)
- Development pathway provided based on template
- Limited marketing activity by Innovation Ventures until a specific milestone is hit


Shared Responsibility to Drive to Commercialization Exit - ~ 8 projects per Portfolio Manager

- Technology enters Innovation Ventures portfolio
- Intellectual property and marketing strategies determined by Innovation Ventures in conjunction with Inventor(s)
- Development pathway discussed based on template, and alignment developed between Innovation Ventures and Inventor(s)
- Technology is potentially eligible to enter Acceleration

Not Pursued for Commercialization

- Technology will not enter Innovation Ventures portfolio
- There will be discussion on what additional information or data, if any, will support moving into the portfolio
- Any agreement related to the invention (e.g., confidentiality agreements, service agreements, research collaboration agreements, sponsored research agreements) can be submitted via [Huron \(HRS\)](#) (if research related) or [Peoplesoft](#) (if not research related)
- Should Inventor(s) choose to continue to develop the technology it would be without CCIV support
- Inventor(s) may submit a new disclosure when additional information or data is available to be reconsidered

How CCIV determines the disposition



Criteria Considered During Disposition

- Is there clinical utility? What would the impact of this invention be if brought to the market?
- What is the relative advantage of the technology as compared to what we know is on the market or in development pipelines?
- Protectability of the competitive advantage (i.e., patentability, copyright, exclusive data)
- Is there a path to development? Is the investigator planning to continue to work on the tech? Are we aware of commercial partners that may exist?
- Feasibility of the tech based on current data
- Market Trends to our knowledge
- Regulatory pathway feasibility based on our experience

Input from CCIV Co-CSOs

- Inventor(s) have the right to appeal the disposition decision to the CCIV co-CSOs
- If co-CSOs overturn Innovation Ventures' disposition decision, the technology shall follow the standard management process as outlined in this document

CCIV Commercialization Process Overview

EVALUATION

Disclosure Submission & Acknowledgement

- Acknowledgement \leq 3 business days of disclosure submission; Urgent patent filing decision within \leq 14 days

Disclosure Reporting & Assessment

- \leq 30 days of disclosure submission

Review Process & Disposition

- \leq 120 days of meeting with Inventor(s)

MANAGEMENT

Initial Commercial Strategy

- \leq 30 days of Review Process & Disposition

Intellectual Property Management

- Timelines determined by patent offices

Marketing

- Ongoing once technology reaches "Marketing" status

Agreement Due Diligence, Negotiation, & Execution

- Timeline determined by partner
- Innovation Ventures to follow up every 2 weeks

Initial Commercial Strategy
(Inventor(s) Driven)



Intellectual Property
Management



Marketing



Agreement Due Diligence,
Negotiation, & Execution

Inventor(s)

≥30 days prior to public disclosure

- Provide update to Innovation Ventures before any public disclosure (e.g., dissertation, abstract submission, poster presentation, presentation outside of internal division, publication submission, discussion outside of immediate collaborators, etc.)

≤ 30 days of an Innovation Ventures request

- See [IP Management process](#)

On an ongoing basis

- Apply to opportunities that may advance the technology:
 - Existing programs identified by Innovation Ventures
 - Other funding opportunities or collaborations with complementary expertise

Innovation Ventures

≤ 30 days of Review Process & Disposition

- Determine who the Inventor(s) are based on the IP policy, and gain initial alignment on any revenue split should the invention be commercialized
- Deliverable:
 - Align on next steps within a template development path
 - Determine whether registration of a Copyright or filing of a non-provisional Patent is warranted

On an ongoing basis

- Identify partner matches that may help advance the technology
- Check-ins with Inventor(s) on progress every 6 months
- Check-ins with Inventor(s) when IP input is needed

Initial Commercial Strategy
(Shared Responsibility)



Intellectual Property
Management



Marketing



Agreement Due Diligence,
Negotiation, & Execution

Inventor(s)

≥ 30 days prior to public disclosure

- Provide update to Innovation Ventures before any public disclosure (e.g., dissertation, abstract submission, poster presentation, presentation outside of internal division, publication submission, discussion outside of immediate collaborators, etc.)

≤ 30 days of an Innovation Ventures request

- See [IP Management process](#)

On an ongoing basis

- Advise on proposed development steps
- Receive feedback on development steps from Innovation Ventures, and Innovation Ventures's advisors and industry contacts
- To the extent resources are available, perform commercially relevant experiments
- Apply for funding that will further the commercial development of the invention
- A clear indication as to what extent the Inventors' desire to continue to work with the industry partner after a potential industry agreement
- Commitment to be willing to serve on an Innovation Ventures committee

Innovation Ventures

≤ 30 days of Review Process & Disposition

- Determine who the Inventor(s) are based on the IP policy, and gain initial alignment on any revenue split should the invention be commercialized
- Review potentially competitive products
- Search of patent/publication literature
- Deliverable:
 - Begin to discuss and align on development steps based on a template development path
 - Determine whether registration of a Copyright is warranted or determine the scope of non-provisional Patent claims

On an ongoing basis

- Seek input from internal and external advisors
- Active IP assessment
- Attempt to match to sources of development funding
- Identify the development steps that will move the invention to a commercial endpoint

CCIV Commercialization Process Overview

EVALUATION

Disclosure Submission & Acknowledgement

- Acknowledgement \leq 3 business days of disclosure submission; Urgent patent filing decision within \leq 14 days

Disclosure Reporting & Assessment

- \leq 30 days of disclosure submission

Review Process & Disposition

- \leq 120 days of meeting with Inventor(s)

MANAGEMENT

Initial Commercial Strategy

- \leq 30 days of Review Process & Disposition

Intellectual Property Management

- Timelines determined by patent offices

Marketing

- Ongoing once technology reaches "Marketing" status

Agreement Due Diligence, Negotiation, & Execution

- Timeline determined by partner
- Innovation Ventures to follow up every 2 weeks

MANAGEMENT

Initial Commercial Strategy



Intellectual Property Management



Marketing



Agreement Due Diligence,
Negotiation, & Execution

Inventor(s)

≥ 30 days prior to public disclosure

- Provide update to Innovation Ventures before any public disclosure (e.g., abstract submission, poster presentation, presentation outside of internal division, publication submission, etc.)

≤ 30 days of an Innovation Ventures request

- Provide Innovation Ventures and external patent counsel with written information related to the invention, as directed by patent manager and portfolio manager
- Availability for ongoing in-person or teleconference meetings
- Complete and sign documents necessary for the patent process
- An invention disclosure if one does not exist on what is being filed, as determined by Innovation Ventures

Innovation Ventures

In compliance with legal deadlines

- Determine inventorship based on patent law
- Determine commercially relevant scope of protection
- Assign and work closely with external patent counsel and cover related costs
- Work with other co-owners or organizations with 3rd party rights
- Report IP progress to sponsors, if relevant

CCIV Commercialization Process Overview

EVALUATION

Disclosure Submission & Acknowledgement

- Acknowledgement \leq 3 business days of disclosure submission; Urgent patent filing decision within \leq 14 days

Disclosure Reporting & Assessment

- \leq 30 days of disclosure submission

Review Process & Disposition

- \leq 120 days of meeting with Inventor(s)

MANAGEMENT

Initial Commercial Strategy

- \leq 30 days of Review Process & Disposition

Intellectual Property Management

- Timelines determined by patent offices

Marketing

- Ongoing once technology reaches "Marketing" status

Agreement Due Diligence, Negotiation, & Execution

- Timeline determined by partner
- Innovation Ventures to follow up every 2 weeks

MANAGEMENT

Initial Commercial Strategy



Intellectual Property Management



Marketing (Shared Responsibility)



Agreement Due Diligence, Negotiation, & Execution

Inventor(s)

≤ 14 days of an Innovation Ventures request

- Inform Innovation Ventures of any industry or investor that they meet or are aware of that may be interested in the invention
- Review drafts of non-confidential marketing materials
- Provide Innovation Ventures with updated data and information relevant to the invention
- Availability for non-confidential, and confidential meetings with industry, as specified by Innovation Ventures

Innovation Ventures

Ongoing basis after market readiness criteria are met

- Set marketing strategy and timeline based on status of invention
- Draft non-confidential marketing materials, if necessary
- Clarify to inventor(s) what materials are non-confidential and what are confidential
- Make non-confidential materials available via Innovation Ventures website, marketing campaigns, partnering meetings, and/or Innovation Ventures connections, as determined by Innovation Ventures
- Perform Denied Party Screenings on foreign entities
- Encourage industry/investors to proceed to enter into a confidentiality agreement

CCIV Commercialization Process Overview

EVALUATION

Disclosure Submission & Acknowledgement

- Acknowledgement \leq 3 business days of disclosure submission; Urgent patent filing decision within \leq 14 days

Disclosure Reporting & Assessment

- \leq 30 days of disclosure submission

Review Process & Disposition

- \leq 120 days of meeting with Inventor(s)

MANAGEMENT

Initial Commercial Strategy

- \leq 30 days of Review Process & Disposition

Intellectual Property Management

- Timelines determined by patent offices

Marketing

- Ongoing once technology reaches "Marketing" status

Agreement Due Diligence, Negotiation, & Execution

- Timeline determined by partner
- Innovation Ventures to follow up every 2 weeks

MANAGEMENT

Initial Commercial Strategy



Intellectual Property
Management



Marketing



Agreement Due Diligence, Negotiation, &
Execution (Shared Responsibility)

Inventor(s)

≤ 14 – 30 days of an Innovation Ventures request

- Availability for meetings with the industry partner and with Innovation Ventures
- Provide feedback to Innovation Ventures of the potential partner
- Consider appropriateness of development path of potential partner
- A specific, written summary of technical know-how to be transferred under the agreement
- A scope of work, if one is called for under the agreement, and budget to be approved by division business contact
- Resolve any conflict of interest or conflict of commitment issues, if needed

Innovation Ventures

Upon interest from industry or investor interest in entering into an agreement for development and/or commercialization


- Assess whether the partner is an appropriate match for the invention
- Negotiate term sheet
- Provide notice to CCHMC conflict committee/Legal/ORCRA/ Div. Dir./SRS of potential COI, as appropriate
- Keep faculty informed of negotiation, and potential impacts on them as a result of the agreement
- Work with internal or external counsel, as necessary, to negotiate and execute agreement

Moving a Project into Acceleration

Shared Responsibility Management process steps hold true whether an invention is in Portfolio Management or Acceleration.

If an invention moves into Acceleration, it may occur at various points during **Shared Responsibility Management**.

HOW INVENTIONS MOVE INTO ACCELERATION



Review Process

Innovation Ventures & External Expertise (as needed)

Project reviews will be presented to the evaluation committee consisting of Innovation Ventures Leadership, with the outcome communicated to the inventor(s) thereafter.

Expectations

Acceleration requires a higher level of commitment from both Inventor(s) and Innovation Ventures.

Ongoing Assessment and Right-Sizing the Portfolio

Transitioning to this SLE

- In order to meet the commitments of this document, we need to review the existing portfolio through this lens
- This transition to review the old portfolio will take time
- Over the 2023 fiscal year we will be implementing a plan to review the existing portfolio through the lens of our new process and criteria

Technologies in the portfolio will be assessed on an ongoing basis by these criteria

- Is there clinical utility? What would the impact of this invention be if brought to the market?
- What is the relative advantage of the technology as compared to what we know is on the market or in development pipelines?
- Protectability of the competitive advantage (i.e., patentability, copyright, exclusive data)
- Is there a path to development? Is the investigator planning to continue to work on the tech? Are we aware of commercial partners that may exist?
- Feasibility of the tech based on current data
- Market Trends to our knowledge
- Regulatory pathway feasibility based on our experience
- Market interest / Feedback from potential licensees
- Responsiveness of the Inventor(s) to CCIV request as outlined throughout the stages

Changing the Disposition of a Technology

- During the course of development, if the assessment of the technology changes, there will be a meeting with the Inventor(s) to discuss the following:
 - The current assessment based on the criteria
 - An estimate of costs expended on the technology to date
 - A determination of the updated disposition
- CCIV continually will seek alignment from the Inventor(s) on disposition decisions. If the Inventor(s) are non-responsive, CCIV will make the decision using its best judgement
- Inventor(s) have the right to appeal the disposition decision to the CCIV co-CSOs, if Inventor(s) indicate their desire to appeal within 15 days of a deadline provided by CCIV

2. Sending and Receipt of Biologic and Copyright Research Tools

Biologic Research Tool Expectations Overview

Researcher	Sponsored Research Services (SRS)	Innovation Ventures	Legal
<ul style="list-style-type: none"> • If sending materials: <ul style="list-style-type: none"> • Submit a complete RT disclosure via the Inventor Portal, and respond to any requested missing information • If sending to a: <ul style="list-style-type: none"> • Not-for-profit organization, then create a Huron (HRS) Agreement record • For-profit organization, then contact Innovation Ventures • If receiving materials regardless of the type of organization, create a Huron (HRS) Agreement record • Respond to any questions from Innovation Ventures and/or SRS 	<ul style="list-style-type: none"> • Manages agreements submitted through the Huron Agreement portal • Responsible for review and negotiation of agreements related to: <ul style="list-style-type: none"> • Any materials being received from another organization • Materials being sent to a not-for-profit organization • Requests guidance from the Researcher on terms that may impact research or publication • Requests guidance from Innovation Ventures on Intellectual Property terms • Requests guidance from Legal for uncommon provisions and the sending of clinical materials and data 	<ul style="list-style-type: none"> • Within 3 days of an RT disclosure submission, an acknowledgement of receipt will be sent • Within 30 days of RT disclosure submission, will assess any restrictions that may exist in sending the materials and communicate these to SRS, if needed • Responsible for negotiating reasonable financial provisions and agreements to send materials to for-profit organizations • Provides guidance to SRS regarding Intellectual Property provisions • Requests guidance from the Researcher on terms that may impact research or publication • Requests guidance from Legal for uncommon provisions • Clinical materials and data generally not provided to for-profit entities 	<ul style="list-style-type: none"> • Reviews uncommon legal provisions in agreements • Provides direction on the sending of clinical materials and data

Copyright Research Tool Expectations Overview



Researcher

- Submit a complete RT disclosure via the [Inventor Portal](#), and respond to any requested missing information
- Contact Innovation Ventures
- Respond to any questions from Innovation Ventures

Innovation Ventures

- Within 3 days of an RT disclosure submission, an acknowledgement of receipt will be sent
- Within 30 days of RT disclosure submission, will assess any restrictions that may exist in sending the materials
- Responsible for negotiating reasonable financial provisions and agreements to send materials to for-profit organizations
- Responsible for review and negotiation of agreements
- Requests guidance from the Researcher on terms that may impact research or publication
- Requests guidance from Legal for uncommon provisions
- Clinical data generally not provided to for-profit entities

Legal

- Reviews uncommon legal provisions in agreements
- Provides direction on the sending of clinical data

3. Sponsored Research

Sponsored Research Expectations Overview

Researcher	Sponsored Research Services (SRS)	Innovation Ventures	Legal
<ul style="list-style-type: none"> • Create a Huron (HRS) Agreement record • Work with the Sponsoring Company on the scope of work • Work with your Financial Analyst/Manager or Business Manager/Director on the budget • Respond to any questions from Innovation Ventures and/or SRS • Submit a complete Invention Disclosure if Innovation Ventures determines there is relevant background intellectual property 	<ul style="list-style-type: none"> • Manages agreements submitted through the Huron Agreement portal • Responsible for review and negotiation of Sponsored Research Agreements • Requests guidance from the Researcher on terms that may impact research or publication • Requests guidance from Innovation Ventures on Intellectual Property terms • Requests guidance from Legal for uncommon provisions 	<ul style="list-style-type: none"> • Provides guidance to SRS regarding Intellectual Property provisions • Requests guidance from the Researcher on terms that may impact research or publication and provides input to Researcher on how this agreement may impact future work • Requests guidance from Legal for uncommon provisions • Clinical materials and data generally not provided to for-profit entities 	<ul style="list-style-type: none"> • Reviews uncommon legal provisions in agreements